A Phase 1, Randomized, Double-Blind, Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK001 in Subjects With Atopic Disease
Phase of Trial: Phase I
Latest Information Update: 05 Jul 2016
At a glance
- Drugs AK 001 (Primary)
- Indications Hypersensitivity
- Focus Adverse reactions; First in man
- Sponsors Allakos
- 27 Jun 2016 Status changed from active, no longer recruiting to completed.
- 19 Jan 2016 Status changed from recruiting to active, no longer recruiting, according to an Allakos Inc. media release.
- 06 Oct 2015 New trial record